Exact Sciences CorporationEXAS
NASDAQ • Healthcare
$104.91
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+23.1% YoY
Gross Margin
70.1%
Health Score
6/10
D/E Ratio
1.05
Confidence
—
Business Snapshot
Exact Sciences is a medical diagnostics company focused on non-invasive cancer screening and diagnostic tests, with its flagship product Cologuard for colorectal cancer. The company operates in the rapidly growing cancer diagnostics market, holding a strong position as a pioneer in stool-based DNA screening. With TTM revenue of $3.25B, it sits in the mid-cap tier, though market capitalisation is not provided in the payload. Its key competitive moat lies in the FDA-approved, guideline-recommended nature of Cologuard, creating a regulatory and commercial barrier for new entrants. The company is still transitioning from heavy investment to a more profitable growth phase, as evidenced by ongoing net losses.
Financial Health
Gross margin improved to 70.1% from 68.6% in the prior year, reflecting better cost management and scale, while net margin remains negative at -6.4%, indicating the company is still unprofitable on a net income basis. The balance sheet is moderately leveraged with a debt/equity ratio of 1.05x, and the current ratio of 2.43x provides ample short-term liquidity...
Risk Assessment
- VALUATION — EV/EBITDA of 75.98x signals an extremely high multiple relative to earnings, leaving little room for error.
- EARNINGS QUALITY — Only 1 of the last 4 quarters beat analyst estimates, indicating low earnings predictability and potential guidance issues.
- REVENUE DECELERATION — Quarterly revenue growth of 3.2% is significantly slower than the 23.1% annual pace, suggesting growth is slowing.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- PROFITABILITY — Net margin of -6.4% and return on equity of -8.5% show the company remains unprofitable,...